Bioenvision to Hold Fiscal 2006 Year-End Financial Results Conference Call Monday, September 11, 2006
September 08 2006 - 1:33PM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal 2006 year-end
financial results at 7 a.m. Eastern Daylight Time on September 11,
2006. Christopher B. Wood, Chairman and CEO and David P. Luci, CFO
and General Counsel, will host an investment conference call
beginning at: 12 p.m. Eastern Daylight Time on September 11, 2006
to discuss these results and to answer questions. Conference Call
Information: Date: 9/11/2006 Time: 12:00PM Eastern Toll free:
866-585-6398 International: 416-849-9626 Web cast:
www.bioenvision.com A replay of the call and web cast will be
available for 14 days. Replay number: 866-245-6755 Replay number
international: 416-915-1035 Replay passcode: 739924 Web cast
replay: www.bioenvision.com About Bioenvision Bioenvision's primary
focus is the acquisition, development, distribution and marketing
of compounds and technologies for the treatment of cancer.
Bioenvision has a broad pipeline of products for the treatment of
cancer, including: Evoltra(R), Modrenal(R) (for which Bioenvision
has obtained regulatory approval for marketing in the United
Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies,
including the OLIGON(R) technology; an advanced biomaterial that
has been incorporated into various FDA approved medical devices and
Suvus(TM), an antimicrobial agent currently in clinical development
for refractory chronic hepatitis C infection. For more information
on Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024